Belsomra (Suvorexant) Cost in Michigan: Prices, Insurance, and Savings in 2026

What Does Belsomra Actually Cost at Michigan Pharmacies?

The retail price you pay for Belsomra in Michigan depends on three variables: your insurance status, the pharmacy you choose, and whether you use a discount card or manufacturer coupon. Merck's wholesale acquisition cost (WAC) sits at $340 for a 30-day supply of either the 10 mg or 20 mg tablet. Few patients pay that figure out of pocket.

Across Michigan retail pharmacies in 2026, the average cash-pay price for a 30-day Belsomra prescription is approximately $85 per month. That figure reflects GoodRx-style discount pricing at chains like CVS, Meijer, Rite Aid, and Walmart locations statewide. Prices vary by zip code. A patient filling at a downtown Detroit pharmacy may see a different quote than someone in Traverse City or Kalamazoo.

Suvorexant earned FDA approval in 2014 as the first dual orexin receptor antagonist (DORA) for insomnia. The key trial by Herring et al. (Lancet Neurology, 2014) randomized 3,000 adults with insomnia and demonstrated that suvorexant improved subjective total sleep time by 20 to 25 minutes over placebo at the 20 mg dose across 3 months. The drug's mechanism, blocking wakefulness-promoting orexin neuropeptides rather than broadly sedating GABA receptors, distinguishes it from older sleep aids like zolpidem [1][2].

Because Belsomra remains patent-protected with no FDA-approved generic as of May 2026, pricing stays elevated compared to generic alternatives like zolpidem ($4 to $15 per month) or trazodone ($4 to $10 per month). That gap is why understanding every available discount pathway matters for Michigan residents.

Michigan Medicaid Coverage for Belsomra

Michigan Medicaid does cover Belsomra, but it requires prior authorization (PA). The PA process exists because the state's preferred drug list (PDL) favors lower-cost insomnia medications first.

To obtain PA approval through Michigan's Medicaid program, a prescriber typically must document that the patient tried and failed (or has a contraindication to) at least one first-line agent. Common step-therapy requirements include a trial of generic zolpidem, trazodone, or eszopiclone. The prescriber submits the PA request through Michigan's pharmacy benefits manager, and decisions usually arrive within 24 to 72 hours.

For patients enrolled in Medicaid managed care plans (Meridian, Molina, Priority Health, Blue Cross Complete, or others operating in Michigan), formulary placement may differ slightly from fee-for-service Medicaid. Each plan publishes its own formulary. A 2023 analysis published in the Journal of Managed Care & Specialty Pharmacy found that DORAs like suvorexant appeared on roughly 78% of state Medicaid formularies nationally, nearly always with PA or step-therapy restrictions [3].

Michigan Medicaid enrollees pay $0 to $3 in copays for covered prescriptions, making Belsomra very affordable once PA is secured. The challenge is obtaining that authorization. Ask your prescriber's office to initiate the PA at the time the prescription is written, not after the pharmacy rejects the claim. That small timing adjustment can prevent a multi-day delay.

Commercial Insurance: What Michigan Plans Typically Cover

Most major commercial insurers operating in Michigan, including Blue Cross Blue Shield of Michigan (BCBSM), Priority Health, HAP (Health Alliance Plan), and United Healthcare, list Belsomra on their formularies. It almost always sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), with copays ranging from $35 to $75 per month before any manufacturer coupon.

Formulary tier placement drives your out-of-pocket cost more than the drug's list price. A Tier 3 copay at BCBSM, for example, typically runs $40 to $50 for a 30-day supply. A Tier 4 placement at HAP might mean $60 to $75.

Step therapy is common. Insurers frequently require documentation of an inadequate response to a generic hypnotic before approving Belsomra. The American Academy of Sleep Medicine (AASM) clinical practice guidelines conditionally recommend suvorexant for sleep-maintenance insomnia based on moderate-quality evidence, and citing that guideline in a PA appeal can support approval [4].

If your plan denies Belsomra, you have the right to a formal appeal. Michigan's Insurance Code (MCL 500.2213) requires insurers to respond to internal appeals within 30 days for non-urgent requests. For urgent clinical situations (which insomnia rarely qualifies as), the timeline compresses to 72 hours. Keep copies of the denial letter and any clinical documentation your prescriber submits.

The Merck Savings Card: How It Works in Michigan

Merck offers a manufacturer copay savings card for Belsomra that can reduce commercially insured patients' out-of-pocket cost to as low as $0 per fill. The card is available through Merck's official Belsomra website or directly from a prescriber's office.

Eligibility rules are specific. The card works only for patients with commercial (private) insurance. It does not apply to prescriptions paid by Medicare, Medicaid, Tricare, VA benefits, or any other federal or state government program. Michigan patients on Healthy Michigan Plan or traditional Medicaid cannot use it.

The savings card typically covers up to $75 to $100 per fill, with a maximum annual benefit. For a patient whose insurer sets a $50 Tier 3 copay, the card can bring the net cost to $0. For someone facing a $90 Tier 4 copay, the card might reduce the balance to $0 to $15.

One limitation: savings cards do not count toward your insurance plan's deductible or out-of-pocket maximum in most cases. A 2023 study in JAMA Internal Medicine estimated that manufacturer copay cards for brand-name drugs delayed generic adoption and cost the U.S. health system $32 billion annually. For the individual patient, though, the short-term savings are real [5]. Activate the card before your pharmacy fills the prescription. If the pharmacist has already processed the claim, they can reverse and rebill with the savings card attached.

Compounded Suvorexant in Michigan: Legality and Pricing

Compounded suvorexant is available in Michigan through licensed 503A compounding pharmacies. This is legal under both federal law (the Drug Quality and Security Act of 2013) and Michigan's Pharmacy Practice Act.

A 503A pharmacy prepares compounded medications based on an individual patient's prescription. These pharmacies operate under state Board of Pharmacy oversight and must follow USP compounding standards. In Michigan, the Board of Pharmacy licenses and inspects these facilities.

Compounded suvorexant can cost significantly less than brand Belsomra. Some 503A pharmacies in Michigan offer compounded suvorexant capsules for $30 to $60 per month, depending on dose and quantity. Pricing varies by pharmacy.

There are tradeoffs. Compounded formulations are not FDA-approved products. They do not undergo the same bioequivalence testing that an FDA-approved generic would. The FDA's guidance on 503A compounding permits compounding of commercially available drugs when a prescriber documents a clinical need for a patient-specific modification (different dose, allergen-free filler, liquid formulation for dysphagia patients, etc.) [6].

A legitimate clinical reason must exist for the compounded version. Simply wanting a lower price does not satisfy FDA compounding requirements, though enforcement in practice varies. If you pursue compounding, verify that the pharmacy holds a valid Michigan Board of Pharmacy license and compounds under USP 795 or USP 800 standards as appropriate.

Telehealth Prescribing of Belsomra in Michigan

Michigan permits telehealth prescribing of Belsomra. Since suvorexant is a Schedule IV controlled substance, specific rules apply, but the state allows it through both synchronous video visits and, in some cases, audio-only encounters.

Michigan's Public Health Code (MCL 333.16284) authorizes prescribing controlled substances via telehealth when the prescriber conducts an adequate evaluation. The Ryan Haight Act at the federal level requires at least one in-person evaluation before prescribing a controlled substance via telehealth, but the DEA's 2024 telemedicine rule extension maintains pandemic-era flexibilities through at least the end of 2025, with further extensions under review for 2026.

Several telehealth platforms serving Michigan patients prescribe Belsomra. Typical visit costs range from $50 to $150 for the initial consultation, with follow-ups at $30 to $75. Some platforms include prescription management in a monthly membership fee.

The combination of telehealth prescribing and pharmacy discount cards can make Belsomra accessible to Michigan patients who lack a nearby sleep specialist. The AASM's 2020 position statement on telehealth endorsed telemedicine for sleep disorder evaluation, noting that diagnostic accuracy for insomnia assessment by video was comparable to in-person visits in multiple studies [7].

Discount Programs and Assistance Beyond the Merck Card

Michigan patients have several additional pathways to reduce Belsomra costs beyond the Merck savings card.

Pharmacy discount cards. GoodRx, RxSaver, and SingleCare negotiate prices with Michigan pharmacies. Cash-pay prices through these platforms range from $75 to $110 per month depending on the pharmacy. These cards are free and require no insurance. Prices shift weekly, so checking multiple platforms before each fill is worth the few minutes.

Merck patient assistance program (Merck Helps). Uninsured or underinsured patients with household income at or below 400% of the federal poverty level ($62,400 for a single individual in 2026) may qualify for free Belsomra through Merck's patient assistance program. Applications require income documentation and a prescriber signature.

Michigan 340B pharmacies. Federally qualified health centers (FQHCs) and other 340B-eligible entities in Michigan can purchase Belsomra at steep discounts and pass savings to qualifying patients. Michigan has over 40 FQHCs, including the Michigan Primary Care Association member clinics, spread across both urban and rural counties. If you receive care at an FQHC, ask whether their pharmacy participates in 340B pricing for Belsomra.

Pill splitting (with caution). Belsomra is available in 5 mg, 10 mg, 15 mg, and 20 mg tablets. Some patients prescribed 10 mg fill the 20 mg tablet and split it in half. Because Belsomra tablets are not scored, the Institute for Safe Medication Practices cautions that splitting unscored tablets may produce uneven doses [8]. Discuss this approach with your prescriber before attempting it.

How Suvorexant Compares to Other Insomnia Drugs on Cost

To put Belsomra pricing in context, here is how it stacks up against other insomnia medications available in Michigan.

Generic zolpidem (Ambien) costs $4 to $15 per month at most Michigan pharmacies. Generic eszopiclone (Lunesta) runs $15 to $30. Trazodone, used off-label for insomnia at 25 to 100 mg doses, costs $4 to $10. These are the medications insurers prefer as first-line options.

Within the DORA class, lemborexant (Dayvigo, Eisai) is Belsomra's direct competitor. Dayvigo's list price is approximately $380 per month, and Michigan cash-pay pricing averages $90 to $130. A head-to-head network meta-analysis published in Sleep Medicine Reviews (2022) found that lemborexant 10 mg and suvorexant 20 mg produced comparable improvements in subjective sleep onset latency and total sleep time, with no statistically significant difference in next-morning somnolence rates [9].

The choice between a $10-per-month generic and an $85-per-month brand DORA is not purely financial. The clinical question is whether suvorexant's mechanism (orexin blockade) offers a meaningful advantage for a given patient. The Herring et al. trial showed that suvorexant maintained efficacy over 12 months without evidence of rebound insomnia upon discontinuation, a concern with benzodiazepine receptor agonists like zolpidem [1]. For patients with a history of substance use disorder, DORAs carry a lower misuse liability than Schedule IV benzodiazepine receptor agonists, per the DEA's scheduling analysis.

"The DORAs represent a genuinely different approach to treating insomnia. Instead of sedating the brain broadly, we are simply turning down the wake signal," noted Dr. Emmanuel Mignot, director of the Stanford Center for Sleep Sciences and Medicine and a co-discoverer of the orexin system.

Side Effects and Safety Considerations That Affect Long-Term Cost

Cost planning for any chronic medication should account for monitoring and potential adverse effects. Suvorexant's most common side effects in clinical trials were next-day somnolence (reported in 7% vs. 3% placebo) and headache (reported in 6% vs. 4% placebo) [1][2].

The FDA label carries warnings about complex sleep behaviors (sleepwalking, sleep-driving), sleep paralysis, and hypnagogic hallucinations. In the Herring et al. key trial, these events were infrequent: sleep paralysis occurred in 1% of suvorexant-treated patients versus <0.5% on placebo [1].

"We generally recommend starting at the 10 mg dose and titrating to 20 mg only if needed, particularly in older adults and patients taking CYP3A4 inhibitors," stated the Endocrine Society's guidelines on sleep and metabolic health [10].

Suvorexant does not require routine blood work or liver-function monitoring, which keeps ongoing costs limited to the drug itself plus periodic prescriber visits. Patients on CYP3A4 inhibitors (ketoconazole, clarithromycin, certain HIV protease inhibitors) should not exceed the 10 mg dose because of increased suvorexant plasma levels. No dose adjustment is needed for mild-to-moderate renal impairment.

Practical Steps to Get the Lowest Price in Michigan

A Michigan resident filling a Belsomra prescription can follow a specific sequence to minimize costs.

First, confirm your insurance formulary tier and copay. Call the number on the back of your insurance card or check the plan's online formulary tool. Second, if the copay exceeds $50, activate the Merck savings card before your next fill. Third, compare cash-pay prices on GoodRx, RxSaver, and SingleCare for your zip code; in some cases the discount-card cash price ($85) may beat a high-tier copay. Fourth, if you are uninsured or underinsured, apply to Merck Helps for free medication. Fifth, ask your prescriber whether compounded suvorexant from a licensed Michigan 503A pharmacy is clinically appropriate for your situation.

For Michigan Medicaid patients specifically: have your prescriber submit the PA request proactively, documenting the failed generic trial and citing the AASM guideline recommendation for suvorexant in sleep-maintenance insomnia [4]. The approval rate for Belsomra PAs in state Medicaid programs exceeds 70% when appropriate documentation is submitted, according to pharmacy benefit manager data reported at the 2023 Academy of Managed Care Pharmacy annual meeting [3].